Liminatus Pharma, Inc. Warrants
LIMNW
Get informed when a big investor buys or sells
+ FollowMarket Cap$338.44M
Close$
$-0.05
146.5% downside
Current Fair Value
146.5% downsideOvervalued by 146.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $338.44 Million |
|---|---|
| Enterprise Value | $338.17 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.43 |
| Beta | 0.7 |
| Outstanding Shares | 23,753,561 |
Return
| Return on Equity | -112569.98% |
|---|---|
| Return on Assets | 7053.56% |
| Return on Invested Capital | -1136.38% |
Valuation & Multiples
| P/E Ratio | -0.26 |
|---|---|
| PEG | 0.26 |
| Price to Sales | - |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.11 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Liminatus Pharma, Inc. Warrants
4 employees
CEO: Chris Kim Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.